NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows …

InvestingPro analysis shows the stock tends to move independently of the market with a beta of -0.03, while analyst targets range from $35.49 to $52.62, suggesting potential upside. Want …

CouponFollow Extension

$35.49
OFF

NewAmsterdam Pharma's SWOT Analysis: Obicetrapib Stock Shows …

3 weeks from now

InvestingPro analysis shows the stock tends to move independently of the market with a beta of -0.03, while analyst targets range from $35.49 to $52.62, suggesting potential upside. Want …

msn.com

$2
OFF

NewAmsterdam Pharma's SWOT Analysis: Obicetrapib Stock Poised …

3 weeks from now

Dec 13, 2024 · NewAmsterdam Pharma (NASDAQ:NAMS), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing treatments for cardiovascular …

investing.com

100%
OFF

NewAmsterdam Pharma Shares Supported By De-risked …

3 weeks from now

Dec 11, 2024 · Catch Investing.com’s top 10 stock picks for 2025 on January 28 @ 4pm GMT / 11 am ET Join Event Get 100% ad-free experience NewAmsterdam Pharma shares supported by …

investing.com

$48.00
OFF

Obicetrapib’s Data Positions NewAmsterdam Pharma Stock For …

3 weeks from now

Dec 30, 2024 · On Monday, H.C. Wainwright initiated coverage on NewAmsterdam Pharma Co NV (NASDAQ:NAMS), issuing a Buy rating with a $48.00 price target. The firm's analyst …

investing.com

33%
OFF

Why Is NewAmsterdam Pharma Stock Trading Higher On …

3 weeks from now

Dec 10, 2024 · Zinger Key Points. NewAmsterdam's Phase 3 trial shows obicetrapib reduces LDL-C by 33% in ASCVD/HeFH patients on maximally tolerated therapy. Safety data show …

benzinga.com

1%
OFF

NewAmsterdam's Stock Rises On Early Sign Cholesterol Drug …

3 weeks from now

Dec 10, 2024 · NewAmsterdam linked obicetrapib to lower rates of all-cause mortality compared to placebo, at 1.1% versus 1.4%, respectively, and a MACE composite, at 4.2% versus 5.2%.

fiercebiotech.com

$2
OFF

Breaking Down NewAmsterdam Pharma (NAMSW) Financial …

3 weeks from now

Understanding NewAmsterdam Pharma Company N.V. Revenue Streams Revenue Analysis. NewAmsterdam Pharma Company N.V. reported a total revenue of $2.7 million for the fiscal …

dcfmodeling.com

FAQs about NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows … Coupon?

Will newamsterdam Pharma's obicetrapib be regulated by 2025?

NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory filing by 2025 and its competitive edge over similar drugs position NAMS for significant market share in cardiovascular therapies. ...

Is obicetrapib a good lead candidate for newamsterdam Pharma?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing cardiovascular drugs, has been garnering attention from investors and analysts alike due to its promising lead candidate, obicetrapib. ...

What are the target prices for newamsterdam pharma's stock?

4 equities research analysts have issued 12 month target prices for NewAmsterdam Pharma's stock. Their NAMS share price forecasts range from $19.00 to $24.00. On average, they predict the company's share price to reach $21.67 in the next year. This suggests a possible upside of 50.7% from the stock's current price. ...

Is obicetrapib stock undervalued?

Investors and analysts are closely monitoring the company's progress, with many viewing the current stock price as undervalued given the potential of obicetrapib. Some analysts suggest there could be significant upside potential, particularly if upcoming trial results continue to be positive. ...

Will skepticism affect newamsterdam pharma's stock performance?

Investor skepticism, particularly following the BROOKLYN trial results which fell slightly short of some expectations, could continue to affect NewAmsterdam Pharma's stock performance. The biopharmaceutical sector is known for its volatility, and stocks can be particularly sensitive to clinical trial results and regulatory decisions. ...

Is obicetrapib a market opportunity?

Analysts project a substantial market opportunity for obicetrapib, with estimates suggesting potential U.S. sales exceeding $1.4 billion. This projection is based on the drug's efficacy, safety profile, and the large population of patients who may benefit from additional LDL-C lowering therapies beyond statins. ...